SRS Capital Advisors Inc. Has $1.78 Million Position in Zoetis Inc. (NYSE:ZTS)

SRS Capital Advisors Inc. lifted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 49.5% during the fourth quarter, Holdings Channel reports. The fund owned 10,913 shares of the company’s stock after buying an additional 3,611 shares during the quarter. SRS Capital Advisors Inc.’s holdings in Zoetis were worth $1,778,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Callahan Advisors LLC lifted its position in shares of Zoetis by 90.4% during the 4th quarter. Callahan Advisors LLC now owns 13,105 shares of the company’s stock valued at $2,135,000 after acquiring an additional 6,221 shares during the period. Pensionfund Sabic lifted its position in shares of Zoetis by 55.6% during the 4th quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock valued at $1,825,000 after acquiring an additional 4,000 shares during the period. PFW Advisors LLC acquired a new position in shares of Zoetis during the 4th quarter valued at $1,764,000. CIBC Asset Management Inc lifted its position in shares of Zoetis by 24.1% during the 4th quarter. CIBC Asset Management Inc now owns 237,369 shares of the company’s stock valued at $38,617,000 after acquiring an additional 46,050 shares during the period. Finally, Alberta Investment Management Corp lifted its position in shares of Zoetis by 2,050.0% during the 4th quarter. Alberta Investment Management Corp now owns 30,100 shares of the company’s stock valued at $4,904,000 after acquiring an additional 28,700 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analysts Set New Price Targets

ZTS has been the topic of a number of research reports. Barclays boosted their target price on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. Morgan Stanley decreased their price target on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. Leerink Partners initiated coverage on shares of Zoetis in a research note on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target for the company. StockNews.com lowered shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Tuesday, February 25th. Finally, Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Two equities research analysts have rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Zoetis has a consensus rating of “Buy” and an average price target of $215.90.

Zoetis Stock Performance

NYSE ZTS opened at $167.58 on Friday. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $200.53. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The firm has a market cap of $75.04 billion, a price-to-earnings ratio of 30.64, a PEG ratio of 2.78 and a beta of 0.90. The company has a fifty day moving average price of $166.30 and a 200-day moving average price of $177.30.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The firm had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. As a group, equities research analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be paid a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.19%. Zoetis’s payout ratio is 36.56%.

Insider Activity at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the sale, the executive vice president now owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 0.16% of the stock is owned by company insiders.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.